FDA Approves Pfizer's Caduet to Lower Hypertension
Caduet combines the drugs amlodipine (Norvasc, Lotrel) and atorvastatin (Lipitor), two widely prescribed cardiovascular medications.
It's the first medicine to treat two different conditions, high blood pressure and high cholesterol.
It is indicated for the treatment of hypertension, chronic stable angina and vasospastic angina (Prinzmetal’s or variant angina). It is also indicated for primary dysbetalipoproteinemia, elevated serum TG levels, hypercholesterolemia and mixed dyslipidemia. In addition, is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia
The recommened initial antihypertensive oral dose of amlodipine is 5 mg once daily with a maximum dose of 10 mg once daily.
Caduet is a combination blood pressure and cholesterol medication marketed by Pfizer Inc. that combines amlodipine (Norvasc), a long-acting calcium channel blocker, and atorvastatin (Lipitor), a HMG-CoA reductase inhibitor.
Amlodipine is used in the treatment of high blood pressure and chest pain (angina), while atorvastatin is used to lower levels of bad cholesterol and triglycerides and raise levels of good cholesterol in the bloodstream.
Novel Therapy Allows Simultaneous Treatment of Two Significant Risk factors for Cardiovascular Disease
Pfizer Inc said today that it has received approval from the U.S. Food and Drug Administration to market its dual therapy medicine Caduet (amlodipine besylate/atorvastatin calcium) for the simultaneous treatment of high blood pressure and high cholesterol.
Developed by Pfizer, Caduet is the first medicine to treat two different conditions-high blood pressure and high cholesterol-in one pill. Caduet contains both Norvasc (amlodipine besylate) for the treatment of high blood pressure and Lipitor (atorvastatin calcium) for high cholesterol.